A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

Summary

This will be a 2-week oral dose study of PF 04991532, performed in patients with type 2 diabetes. Safety, pharmacokinetics (how the drug is distributed in the body), and pharmacodynamics (how the drug works in the body) will be studied. Patients may be asked to wash off their diabetes medication for 4-6 prior to study drug administration, and they will remain in the clinical research unit for a total of 20 days for baseline tests, 2 weeks of dosing, and some follow up tests.

Timeline

Start

2011-12

Primary completion

2012-05

Completion

2012-05

Drugs

Indications